Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2002

Content (12 Articles)

Human Progesterone Receptor Gene Polymorphism PROGINS and Risk for Breast Cancer in Austrian Women

Gerhild Fabjani, Dan Tong, Klaus Czerwenka, Eva Schuster, Paul Speiser, Sepp Leodolter, Robert Zeillinger

Urinary 2-Hydroxyestrone/16α-Hydroxyestrone Ratio and Family History of Breast Cancer in Premenopausal Women

Giske Ursin, Stephanie London, Dongyun Yang, Chiu-Chen Tseng, Malcolm C. Pike, Leslie Bernstein, Frank Z. Stanczyk, Elisabet Gentzschein

Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI

C. Balu-Maestro, C. Chapellier, A. Bleuse, I. Chanalet, C. Chauvel, R. Largillier

Letter to the Editor

Elda Tagliabue, Roberto Agresti, Cristina Ghirelli, Daniele Morelli, Sylvie Ménard

Letter to the Editor

Elda Tagliabue, Roberto Agresti, Cristina Ghirelli, Daniele Morelli, Sylvie Ménard

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine